Showing 673 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

Clinical trials

Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely

Editor's pick
Forbes
22 January 2014
New & experimental HIV treatments

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

Editor's pick
ViiV Healthcare press release
21 January 2014
The search for a cure

NIH-created toxin can kill HIV-infected cells that persist despite treatment

Editor's pick
Eurekalert Medicine & Health
10 January 2014
HIV treatment for children & young people

Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension

Editor's pick
Wall Street Journal
9 January 2014
New & experimental HIV treatments

Vertex's VX-765 holds promise for HIV treatment

Editor's pick
Motley Fool
7 January 2014
New & experimental HIV treatments

New anti-HIV drug target identified

Editor's pick
Medical Xpress
19 December 2013
New & experimental HIV treatments

Lupin launches HIV drug in the US

Editor's pick
The Hindu
19 December 2013
Changing treatment

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

Editor's pick
Gilead press release
16 December 2013
The search for a cure

Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load

Editor's pick
Sangamo Biosciences press release
10 December 2013
New & experimental HIV treatments

Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

Editor's pick
European Medicines Agency
26 November 2013
New & experimental HIV treatments

Gilead's Vitekta Gets Approval in European Union

Editor's pick
Wall Street Journal
19 November 2013
Treatment guidelines

Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

Editor's pick
AIDS Info
31 October 2013
New & experimental HIV treatments

Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia

Editor's pick
Sangamo press release
29 October 2013
New & experimental HIV treatments

ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine

Editor's pick
Viiv Healthcare
23 October 2013
New & experimental HIV treatments

HIV Dual Therapy Matches Standard Triple Cocktail

Editor's pick
MedPage Today
19 October 2013
New & experimental HIV treatments

MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

Editor's pick
NEJM Journal Watch
17 October 2013
The search for a cure

Elusive secret of HIV long-term immunity

Editor's pick
EurekAlert!
17 October 2013
Drug interactions & pharmacokinetics

Merck plans phase III study of once-daily raltegravir (Isentress)

Editor's pick
Merck press release
16 October 2013
New & experimental HIV treatments

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Editor's pick
News Medical Net
15 October 2013
New & experimental HIV treatments

Viriom Reports Clinical Efficacy Data for VM-1500, a New HIV NNRTI

Editor's pick
Marketwired (press release)
8 October 2013
The search for a cure

Gladstone lab uncovers a potential HIV cure — and it's already a drug

Editor's pick
San Francisco Business Times
6 October 2013
PrEP

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Editor's pick
The Body Pro
6 October 2013
New & experimental HIV treatments

From sky high to CHAI – what needs to be done about dolutegravir pricing?

Editor's pick
HIV I-Base
2 October 2013
New & experimental HIV treatments

European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Editor's pick
Gilead press release
26 September 2013